GlassScriptPhysician profile
Brittany Panico
NPI 1811253677
$373,585.87
in general payments reported to CMS, 2019-2025
37 companies · $152K in 2025
The $152K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $3,063 · 2021: $4,870 · 2022: $3,775 · 2023: $56K · 2024: $139K · 2025: $152K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $197K · Consulting Fee: $61K · Travel and Lodging: $35K · Honoraria: $31K · Food and Beverage: $22K · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $197,187.97 |
| Consulting Fee | $61,233.05 |
| Travel and Lodging | $35,170.79 |
| Honoraria | $31,050.00 |
| Food and Beverage | $22,411.26 |
| Education | $104.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $214,209.77 | 2020-2025 | Krystexxa, Uplizna, Otezla |
| Abbvie INC. | $47,866.03 | 2019-2025 | |
| Horizon Therapeutics Plc | $38,669.82 | 2021-2023 | Krystexxa, Tepezza |
| Novartis Pharmaceuticals Corporation | $24,811.63 | 2021-2025 | Cosentyx |
| Ucb, INC. | $21,235.42 | 2021-2025 | Bimzelx, Cimzia |
| Sobi, INC | $14,908.87 | 2021-2025 | |
| Janssen Biotech, INC. | $3,461.97 | 2020-2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $2,884.10 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $1,075.06 | 2021-2025 | Benlysta |
| Pfizer INC. | $862.77 | 2021-2025 | |
| Lilly USA, LLC | $483.61 | 2021-2025 | Taltz, Olumiant |
| Mallinckrodt Hospital Products INC. | $399.10 | 2022-2025 | Acthar |
| Genzyme Corporation | $341.99 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $225.81 | 2021-2024 | Lupkynis |
| Ani Pharmaceuticals, INC. | $223.88 | 2024-2025 | Purified Cortrophin Gel |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $219.28 | 2020-2025 | Tymlos |
| Organon LLC | $215.85 | 2023-2025 | Hadlima, Renflexis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.61 | 2020-2024 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $183.53 | 2020-2025 | Orencia |
| Medtronic, INC. | $179.45 | 2023 | |
| Kestra Medical Technology Services, INC. | $133.42 | 2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $128.77 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $128.07 | 2021-2023 | Opsumit, Uptravi |
| Alexion Pharmaceuticals, INC. | $112.67 | 2024-2025 | Strensiq |
| Impulse Dynamics (USA) INC. | $89.80 | 2024 | Optimizer |
| Fresenius Kabi USA, LLC | $69.78 | 2023-2024 | Idacio |
| Biocon Biologics INC | $59.50 | 2024 | Hulio |
| Ferring Pharmaceuticals INC. | $46.74 | 2024 | Euflexxa |
| Janssen Scientific Affairs, LLC | $35.86 | 2023-2024 | Tremfya |
| Vertos Medical, INC. | $23.66 | 2023 | Mild Device Kit |
| Nevro Corp. | $19.02 | 2024 | Senza |
| Hikma Pharmaceuticals USA | $18.32 | 2022 | |
| Abbott Laboratories | $16.88 | 2025 | Proclaim |
| Teva Pharmaceuticals USA, INC. | $15.92 | 2024 | Truxima |
| Genentech USA, INC. | $14.11 | 2025 | Actemra |
| Sandoz INC. | $13.44 | 2023 | Hyrimoz |
| Kiniksa Pharmaceuticals, LTD. | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Panico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.